Moderna
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1150
- Registration Number
- NCT06067230
- Locations
- πΊπΈ
Lenzmeier Family Medicine - CCT - PPDS, Glendale, Arizona, United States
πΊπΈFoothills Research Center - CCT - PPDS, Phoenix, Arizona, United States
πΊπΈFiel Family & Sports Medicine - PC - CCT - PPDS, Tempe, Arizona, United States
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults β₯65 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1900
- Registration Number
- NCT06060457
- Locations
- πΊπΈ
Centricity Research, Columbus, Ohio, United States
πΊπΈSouth Florida Research Center, Inc., Miami, Florida, United States
πΊπΈSuncoast Research Associates, LLC, Miami, Florida, United States
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT06033261
- Locations
- πΊπΈ
Accel Clinical Sites Network - Cahaba Medical Care, Birmingham, Alabama, United States
πΊπΈAcclaim Clinical Research, San Diego, California, United States
πΊπΈNoble Clinical Research, Tucson, Arizona, United States
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From β₯18 Years of Age to <50 Years of Age
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 351
- Registration Number
- NCT05995275
- Locations
- π¬π§
Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom
π¬π§Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
π¬π§Barts Health NHS Trust, London, United Kingdom
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1285
- Registration Number
- NCT05992935
- Locations
- πΊπΈ
ARK Clinical Research, LLC, Long Beach, California, United States
πΊπΈOptimal Research, Peoria, Illinois, United States
πΊπΈRochester Clinical Research, Inc, Rochester, New York, United States
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 807
- Registration Number
- NCT05975099
- Locations
- πΊπΈ
Clinical Research Consulting, LLC, Milford, Connecticut, United States
πΊπΈStamford Therapeutics Consortium, Stamford, Connecticut, United States
πΊπΈChase Medical Research, LLC, Waterbury, Connecticut, United States
A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1504
- Registration Number
- NCT05972174
- Locations
- π¬π§
Royal Victoria Infirmary, Newcastle upon Tyne, England, United Kingdom
π¬π§University Hospitals Birmingham, Birmingham, London, United Kingdom
π¬π§Chelsea and Westminster Hospital, London, United Kingdom
A Study of the Effectiveness of Moderna COVID-19 Vaccine
- Conditions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 1000000
- Registration Number
- NCT05933304
- Locations
- πΊπΈ
Kaiser Permanente Southern California, Pasadena, California, United States
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- ModernaTX, Inc.
- Registration Number
- NCT05918250
- Locations
- πΊπΈ
Ohio State University Hospital, Columbus, Ohio, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
πΊπΈUniversity of Miami Health System, Miami, Florida, United States
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
- Conditions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 13309
- Registration Number
- NCT05894499
- Locations
- π―π΅
CMIC Co., Ltd., Tokyo, Japan